Literature DB >> 10741389

Induction of resistance to active experimental allergic encephalomyelitis by myelin basic protein-specific Th2 cell lines generated in the presence of glucocorticoids and IL-4.

F Ramírez1, D Mason.   

Abstract

We have produced T cell lines with a Th2 phenotype in the presence of IL-4 and the glucocorticoid dexamethasone (DEX). IL-4 and DEX together were more effective in inducing a Th2 response than IL-4 alone. Myelin basic protein (MBP)-specific Th2 lines were obtained and their ability to induce experimental allergic encephalomyelitis (EAE) was studied. Lines treated with IL-4 and DEX did not transfer passive EAE and did not induce cellular infiltration into the central nervous system as opposed to the encephalitogenic Th1 lines. Lines treated with IL-4 and DEX did not protect animals from the effect of encephalitogenic Th1 lines when the two were injected together. However, a high proportion of animals injected with IL-4 + DEX-treated lines became refractory to the development of EAE after immunization with MBP; that is, it was possible to induce resistance to active EAE without prior episodes of disease. Interestingly, animals injected with T cell lines had accelerated antibody responses against MBP and the predominant isotype was dependent on the cytokines synthesized by the T cell line injected. There was not evidence that the resistance to active EAE was due to anergy of MBP-reactive cells or the action of CD8+ cells. Our data suggest that MBP-specific T cell lines prevent the induction of disease by deviating the reactivity to MBP from a cell-mediated to a humoral one and not merely from a Th1 to a Th2 response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741389     DOI: 10.1002/1521-4141(200003)30:3<747::AID-IMMU747>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses.

Authors:  Jens van den Brandt; Fred Lühder; Kirsty G McPherson; Katrien L de Graaf; Denise Tischner; Stefan Wiehr; Thomas Herrmann; Robert Weissert; Ralf Gold; Holger M Reichardt
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

2.  Natural killer type 2 bias in remission of multiple sclerosis.

Authors:  K Takahashi; S Miyake; T Kondo; K Terao; M Hatakenaka; S Hashimoto; T Yamamura
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

3.  Role of γδ T cells in antibody production and recovery from SFV demyelinating disease.

Authors:  Farinaz Safavi; Jason P Feliberti; Cedric S Raine; Foroozan Mokhtarian
Journal:  J Neuroimmunol       Date:  2011-05-25       Impact factor: 3.478

4.  Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis.

Authors:  Zizhen Kang; Cengiz Zubeyir Altuntas; Muhammet Fatih Gulen; Caini Liu; Natalia Giltiay; Hongwei Qin; Liping Liu; Wen Qian; Richard M Ransohoff; Cornelia Bergmann; Stephen Stohlman; Vincent K Tuohy; Xiaoxia Li
Journal:  Immunity       Date:  2010-03-18       Impact factor: 31.745

Review 5.  More stories on Th17 cells.

Authors:  Alexandre S Basso; Hilde Cheroutre; Daniel Mucida
Journal:  Cell Res       Date:  2009-04       Impact factor: 25.617

6.  Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis.

Authors:  Dionne P Robinson; Sally A Huber; Mohamad Moussawi; Brian Roberts; Cory Teuscher; Rebecca Watkins; Arthur P Arnold; Sabra L Klein
Journal:  Biol Sex Differ       Date:  2011-08-01       Impact factor: 5.027

7.  In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

Authors:  Franck J Barrat; Daniel J Cua; André Boonstra; David F Richards; Chad Crain; Huub F Savelkoul; René de Waal-Malefyt; Robert L Coffman; Catherine M Hawrylowicz; Anne O'Garra
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.